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Objective:  
Stress-induced hyperglycaemia may negatively impact outcomes in critically ill patients. Continuous glucose 
monitoring (CGM) devices measure blood glucose (BG) every 5 minutes and enable analysis of high frequency 
dynamics like glucose complexity. Two recent studies in critically ill patients used Detrended Fluctuation 
Analysis (DFA) to quantify glucose complexity and concluded increased complexity, indicating a more normal, 
healthy regulatory response, was associated with reduced mortality. 
Method:  
CGM data from 10 patients in the Christchurch Hospital ICU with 3 CGM devices per-patient:  1 Medtronic 
Guardian Real-Time monitor in the abdomen; and 2 Medtronic iPro2 recorders located in the abdomen and the 
thigh, enabling inter-site and inter-device comparisons. Glucose complexity was quantified using DFA. For a 
self-similar time series, the scale invariant structure can be described by 𝑋(𝑐𝑡) =  𝑐𝐻𝑋(𝑡). The power law 
exponent, H, was used as the basis for comparison, where a lower value indicates greater complexity.  
Results:  
Retrospectively calibrated iPro2 CGMs reported significantly higher scaling exponents: H = 1.56 [1.46 – 1.60] 
compared to Guardian Real-Time devices: H = 1.43 [1.37 - 1.48] (p = 0.03). Scaling exponents of patients who 
lived were H = 1.51[1.46 – 1.57] versus H = 1.47[1.39 – 1.59] for patients who died (p = 0.5). Using prior study 
results to segregate mortality showed that none of the 8 patients in this study had all 3 CGM devices indicating a 
single, or correct, outcome.  
Conclusion:  
These results show a much stronger association between glucose complexity and sensor/device type are far more 
strongly associated than glucose complexity and patient outcome, where which was an outcome of prior studies 
used using mixed device types.  Further investigations of glucose complexity are required before solid 
conclusions can be drawn. 
 
 
 
 
